Publications

Previous Studies

  • Generation of a core set of items to develop classification criteria for Scleroderma renal crisis using consensus methodology. Butler EA, Baron M, Fogo AB, Frech T, Ghossein C, Hachulla E, Hoa S, Johnson SR, Khanna D, Mouthon L, Nikpour M, Proudman S, Steen V, Stern E, Varga J, Denton C, Hudson M; Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group. Arthritis Rheumatol. 2019 Jan 7. doi: 10.1002/art.40809. PMID: 30614663

  • The patient experience of Raynaud’s phenomenon in systemic sclerosis. Pauling JD, Saketkoo LA, Matucci-Cerinic M, Ingegnoli F, Khanna D. Rheumatology (Oxford) 2019 Jan 1;58(1):18-26 doi: 10.1093/rheumatology/key026.

  • A multi-national qualitative research study exploring the patient experience of Raynaud’s phenomenon in systemic sclerosis: A Scleroderma Clinical Trials Consortium Vascular Working Group initiative. Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, Frech TM, Ingegnoli F, Dures E, Robson J, McHugh NJ, Herrick AL, Matucci-Cerinic M, Khanna D, Hewlett S. Arthritis Care & Research 2018 Sep;70(9):1373-1384

  • Evolving symptoms of Raynaud’s phenomenon in systemic sclerosis are associated with physician and patient-reported assessments of disease severity. Pauling JD, Reilly E, Smith T, Frech TM. Arthritis Care & Research 2018 (ePub ahead of print)

  • Patient perceptions of the Raynaud’s Condition Score diary provide insight into its performance in clinical trials of Raynaud's phenomenon. Pauling JD, Saketkoo LA & Domsic RT. Arthritis & Rheumatology 2018 Jun;70(6):973-974.

  • An interim report of the Scleroderma Clinical Trials Consortium working groups. Baron, M., Kahaleh, B., Bernstein, E. J., Chung, L., Clements, P. J., Denton, C… Vacca, A. Journal of Scleroderma and Related Disorders (2018). https://doi.org/10.1177/2397198318783926 

  • Exploring the patient experience of digital ulcers in systemic sclerosis. Hughes M & Pauling JD. Seminars in Arthritis & Rheumatism 2018 (ePub ahead of print) DOI: 0.1016/j.semarthrit.2018.08.001

  • Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP. J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231. PMID: 28516167

  • Towards developing criteria for scleroderma renal crisis: A scoping review. Hoa S, Stern EP, Denton CP, Hudson M; Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group Investigators of the Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group. Autoimmun Rev. 2017 Apr;16(4):407-415. doi: 10.1016/j.autrev.2017.02.012. Review. PMID: 28212921

  • Measures of disease status in systemic sclerosis: A systematic review. Tay T, Ferdowsi N, Baron M, Stevens W, Hudson M, Proudman SM, Nikpour M; Damage Index Working Group of the Scleroderma Clinical Trials Consortium. Semin Arthritis Rheum. 2017 Feb;46(4):473-487. doi: 10.1016/j.semarthrit.2016.07.010. PMID: 27765344

  • Calcinosis is associated with digital ulcers and osteoporosis in patients with Systemic Sclerosis: A Scleroderma Clinical Trials Consortium Study. Valenzuela A, Baron M, the Canadian Scleroderma Research Group, Herrick A, Proudman S, Stevens W, the Australian Scleroderma Interest Group, Rodriguez-Reyna T, Vacca A, Medsger TA, Fiorentino D, Chung L. Semin Arthritis Rheum. 2016 Dec;46(3):344-349. [PMID: 27371996]

  • Validation of a novel radiographic scoring system for calcinosis affecting the hands of patients with systemic sclerosis. Chung L, Valenzuela A, Fiorentino D, Stevens K, Li S, Harris J, Hutchinson C, Assassi S, Beretta L, Lakshminarayanan S, Rodriguez-Reyna TS, Denton CP, Taillefer RG, Herrick AL, Baron M; Scleroderma Clinical Trials Consortium Calcinosis Working Group. Arthritis Care Res (Hoboken). 2015 Mar;67(3):425-30. doi: 10.1002/acr.22434. PMID: 25155948

  • Validation of a Novel Radiographic Scoring System for Calcinosis Affecting the Hands of Patients with Systemic Sclerosis. Chung L, Valenzuela A, Fiorentino D, Stevens K, Li S, Harris J, Hutchinson C, Assassi S, Beretta L, Lakshminarayanan S, Rodriguez-Reyna TS, Denton CP, Taillefer RG, Herrick AL, Baron M; on behalf of the Scleroderma Clinical Trials Consortium Calcinosis Working Group. Arthritis Care Res (Hoboken). 2014 Aug 22. [PMID: 25155948]

  • Cardiac arrhythmias and conduction defects in systemic sclerosis. Vacca A, Meune C, Gordon J, Chung L, Proudman S, Assassi S, Nikpour M, Rodriguez-Reyna TS, Khanna D, Lafyatis R, Matucci-Cerinic M, Distler O, Allanore Y; Scleroderma Clinical Trial Consortium Cardiac Subcommittee. Rheumatology (Oxford). 2014 Jul;53(7):1172-7.

  • Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, Pope JE, Polisson RP, Streisand JB, Seibold JR; Scleroderma Clinical Trials Consortium. Arthritis Rheum. 2012 Oct;64(10):3420-9. doi: 10.1002/art.34427. PMID: 22328195

  • Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. Walker KM, Pope J; participating members of the Scleroderma Clinical Trials Consortium (SCTC); Canadian Scleroderma Research Group (CSRG). Semin Arthritis Rheum. 2012 Aug;42(1):42-55. doi: 10.1016/j.semarthrit.2012.01.003. PMID: 22464314

  • Clinical trial design in scleroderma: where are we and where do we go next? Chung L, Denton CP, Distler O, Furst DE, Khanna D, Merkel PA; Scleroderma Clinical Trials Consortium. Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S97-102. PMID: 22691217

  • Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS). Pope J. Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S98-111. doi: 10.1002/acr.20598. Review. No abstract available. PMID: 22588774

  • Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. Walker KM, Pope J; Scleroderma Clinical Trials Consortium; Canadian Scleroderma Research Group. J Rheumatol. 2011 Jul;38(7):1326-8. doi: 10.3899/jrheum.101262. PMID: 21459952

  • Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA Jr, Sanders ME, Maranian P, Seibold JR; Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Arthritis Rheum. 2009 Apr;60(4):1102-11. doi: 10.1002/art.24380. PMID: 19333948

  • Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, Matucci-Cerinic M, Denton CP, Mayes MD, Steen VD, Varga J, Furst DE; Scleroderma Clinical Trials Consortium co-authors. Ann Rheum Dis. 2008 May;67(5):703-9. 

Image

Pay Membership Fees

If you are a newly accepted member of the SCTC, please select Initial Fee at $250.00 USD.
If you are a returning member of the SCTC, please select the option of Annual Fee at $200.00 USD.
If your institution is unable to use PayPal, please contact admin@sclerodermaclinicaltrials.org.

Membership Fees



© 2019 Scleroderma Clinical Trials Consortium. Designed By Kangablu Ltd